News and Press Releases
ELIX Polymers obtains gold in the EcoVadis certification, cementing its leadership in sustainability
16 January 2025 – Tarragona, Spain – ELIX Polymers, global leader in the manufacture of thermoplastics, has renewed its EcoVadis certification with an outstanding gold rating. This recognition not only...
Category: Manufacturing and Packing, Pharmaceutical
Posted: January 16, 2025
Polígono Industrial - Ctra. de Vilaseca - La Pineda s/n, 43110, Tarragona, Spain
Registration Opens for INTERPHEX 2025 | April 1-3 in NYCLearning Lab Conference Schedule, Show Floor Content,and New Features Announced
15 January 2025 – New York City, NY, US – Join thousands of industry professionals at INTERPHEX, the premier pharmaceutical and biotechnology event taking place April 1-3, 2025, at the...
Category: Pharmaceutical
Posted: January 15, 2025
Terumo Launches its Injection Filter Needle, a first step of the INFINO™ -Development Program, to extend the choice for hypodermic and intravitreal injections
15 January 2024 – Leuven, Belgium – Terumo Corporation (TSE: 4543) today announced the global launch of the Terumo Injection Filter Needle, a first step of the INFINO™ -Development Program. Indicated for hypodermic as...
Category: Drug Delivery, Manufacturing and Packing
Posted: January 15, 2025
Er-Kim Announces Exclusive Distribution Agreement with the MEDICE Health Family For Vafseo in Central & Eastern Europe
Collaboration will support access of an alternative treatment to improve the lives of people impacted by anemia caused by chronic kidney disease 14 January 2025 -- Warsaw, Poland -- Er-Kim,...
Category: Drug Delivery, Logistics, Other, Pharmaceutical
Posted: January 14, 2025
Akat Mah. Ebulula Mardin Cad. Maya Meridien İş Merkezi No: 16 Daire: 25 34335 Beşiktaş/İstanbul
PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy
14 January 2025 -- Paris, France -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has submitted a Clinical...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 14, 2025
PariSanté Campus, 2-10 Rue d’Oradour-sur-Glane, 75015 Paris
CN Bio signs strategic partnership with Primetech Corporation to establish distribution channel for OOC solutions in Japan
Agreement establishes direct distribution channel for customers in Japan, providing local support and expertise Partnership solidifies CN Bio’s presence in Asian markets and supports ongoing global expansion. 14 January 2025...
Category: Biotechnology, Logistics, Other, Pharmaceutical
Posted: January 14, 2025
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
Indication expands to include treatment-naïve patients The 2021 conditional approval in previously treated patients converted to full approval. 14 January 2025 -- Hong Kong, Shanghai, and New Jersey, US --...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2025
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland
AGAMREE® is approved by MHRA for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in UK 14 January 2025 -- Pratteln, Switzerland -- Santhera Pharmaceuticals...
Category: Other, Pharmaceutical
Posted: January 14, 2025
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy
German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid tumors 14 January...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2025
GILEAD AND LEO PHARMA ENTER INTO STRATEGIC PARTNERSHIP TO ACCELERATE DEVELOPMENT OF ORAL STAT6 PROGRAM WITHPOTENTIAL IN MULTIPLE INFLAMMATORY DISEASES
11 January 2025 – Foster City, California, US and Ballerup, Denmark – Gilead Sciences, Inc. (Nasdaq: GILD) andLEO Pharmatoday announced a strategic partnership to accelerate the development and commercialization of...
Category: Pharmaceutical
Posted: January 13, 2025
Exclusive UniSafe® distribution agreement between Owen Mumford and NIPRO exceeds expectations in Japan with new biosimilar launch
13 January 2025 – Oxford, UK – Owen Mumford, a global leader in medical devices, is pleased to announce that its exclusive agreement with Osaka-based NIPRO CORPORATION (NIPRO) to distribute...
Category: Drug Delivery, Manufacturing and Packing
Posted: January 13, 2025
S&K Label becomes Coveris Brno – Teaming up for Sustainable Label Solutions
13 January 2024 – Vienna, Austria – Coveris announces the full integration of S&K LABEL spol. s r.o., Czech Republic, (S&K LABEL) into the Coveris Group. The acquisition in the Czech...
Category: Manufacturing and Packing, Pharmaceutical
Posted: January 13, 2025
Swissmedic Inspection Success Highlights Excellence at CARBOGEN AMCIS Vionnaz Site
13 January 2025 -- Bubendorf, Switzerland -- Switzerland-based CARBOGEN AMCIS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce the successful completion of a Swissmedic...
Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: January 13, 2025
Revolutionising Delivery and Advancing Sustainability: Capsule innovation and 3D printing transform pharma for a future of precision and ethical solutions.
Dr. Subhashis Chakraborty, General Manager, Head - Global Product Management, ACG Capsules – ACG: “In 2025, advancements in manufacturing technology and polymer science are revolutionising the capsule industry, driving the...
Category: Drug Discovery, Pharmaceutical
Posted: January 13, 2025
AbbVie’s SKYRIZI® (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis
Risankizumab will be available on the NHS in Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to,...
Category: Clinical Trials, Pharmaceutical
Posted: January 13, 2025
